Disc Medicine, Inc. (IRON) Stock

Disc Medicine, Inc. (IRON) is a Healthcare stock trading at $70.82 (as of 2026-06-18), with a market capitalization of $2.66B and a trailing P/E of -10.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.

Valuation — source: SEC EDGAR (first-party)
Price	$70.82
Market Cap	$2.66B
P/E Ratio	-10.5
EV / EBITDA	-9.8
Price / Book	3.86
DCF Value (model)	$-79.26
DCF Upside vs Price	-211.9%

Profitability & Growth — source: SEC EDGAR
Return on Equity	-35.1%
Debt / Equity	0.04
Current Ratio	24.00

Valuation vs Sector & Industry
Stock P/E	-10.5
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-150.0%
vs Industry	-160.7%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	FMR LLC ($357.23M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	John D. Quisel
Employees	94
Country	US
IPO Date	2020-08-12

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.